*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States.

*The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*

Genscript Biotech Corporation
(*Incorporated in the Cayman Islands with limited liability*)
(**Stock code: 1548**)

COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE

Joint Overall Coordinators and Joint Placing Agents
(in alphabetical order)

Reference is made to the announcement of Genscript Biotech Corporation (the "**Company**) dated 11 September 2026 in respect of the placing of new Shares under the general mandate (the "**Placing Announcement**"). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as those defined in the Placing Announcement.

COMPLETION OF THE PLACING

The Board is pleased to announce that all the conditions set out in the Placing Agreement have been fulfilled and the Completion took place on 15 September 2026 in accordance with the terms and conditions of the Placing Agreement.

A total of 77,126,000 Placing Shares, representing approximately 3.50% of the existing issued share capital of the Company immediately before completion of the Placing, and approximately 3.38% of the issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately after completion of the Placing, have been successfully placed to not less than six Placees at the Placing Price of HK$30.50 per Share.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the Placees and their respective ultimate beneficial owner(s) (where applicable) is an Independent Third Party. Furthermore, as far as the Company is aware, none of the Placees and their ultimate beneficial owners will become a substantial shareholder (as defined in the Listing Rules) of the Company as a result of the Placing.

The gross proceeds to the Company from the Placing are approximately HK$2,352.3 million, and the net proceeds from the Placing, after deducting the placing commission and other relevant costs and expenses of the Placing, amounted to approximately HK$2,327.1 million. Please refer to the Placing Announcement for the details of the intended use of proceeds.

As disclosed in the Placing Announcement, following the Completion, the Company will make filings with the regulatory authorities in the PRC in accordance with the relevant applicable laws and regulations, including the CSRC Filings.

EFFECTS ON THE SHAREHOLDING STRUCTURE OF THE COMPANY AS A RESULT OF THE PLACING

The shareholding structure of the Company (i) immediately before the Completion; and (ii) immediately upon the Completion are set out below:

	Immediately before the Completion		**Immediately upon the Completion**	
Shareholders	**Number of issued Shares**	**Approximate % of issued share capital of the Company** *(%)*[Note 1]	**Number of issued Shares**	**Approximate % of issued share capital of the Company** *(%)*[Note 1]
GenScript Corporation[Note 2]	799,999,123	36.31	799,999,123	35.08
Other non-public Shareholders	4,016,989	0.18	4,016,989	0.18
The Placees	-	-	77,126,000	3.38
Other public Shareholders	1,399,344,351	63.51	1,399,344,351	61.36
Total	**2,203,360,463**	**100.00**	**2,280,486,463**[Note 3]	**100.00**

Note:

1. The aggregate of the percentage figures in the table above may not add up to the relevant subtotal or total percentage figures shown due to rounding of the percentage figures to two decimal places.

2. GenScript Corporation is a company incorporated in the State of Delaware in the U.S. and one of the controlling shareholders of the Company. As at the date of this announcement, it was owned as to approximately 10.87%, 20.19%, 4.86%, 0.93%, 0.96%, 2.44%, 22.76%, 22.66%, 2.37%, 8.06%, 1.78%, 1.05%, and 1.07% by Frank Zhang, the Zhang Trust, Weihong Jin, the Jin 2025 Trust, the Jin 2023 Trust, the Jin 2026 Trust, Larry Wang, Karen Wu (in her own name and through certain family trustees), Sally Wang, the Wang Trust, the Wang 2026 Trust, Yingjun Mu and Charity B-Community Foundation of New Jersey, respectively.

3. Represents the total number of issued Shares immediately upon the Completion, assuming that no new Shares are issued and allotted under the Company's post-IPO share option scheme approved and adopted by written resolutions of its then sole shareholder on 7 December 2015.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 15 September 2026

As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang, Dr. Li Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Andy Cheung, Mr. Ethan Pan, Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.